Clearside Historical Cash Flow

CLSD Stock  USD 1.05  0.02  1.87%   
Analysis of Clearside Biomedical cash flow over time is an excellent tool to project Clearside Biomedical future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 3.1 M or Begin Period Cash Flow of 50.8 M as it is a great indicator of Clearside Biomedical ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Clearside Biomedical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Clearside Biomedical is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.

About Clearside Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Clearside balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Clearside's non-liquid assets can be easily converted into cash.

Clearside Biomedical Cash Flow Chart

At present, Clearside Biomedical's Depreciation is projected to increase significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 9.8 M, whereas Change In Cash is projected to grow to (18.5 M).

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most accounts from Clearside Biomedical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Clearside Biomedical current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.At present, Clearside Biomedical's Depreciation is projected to increase significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 9.8 M, whereas Change In Cash is projected to grow to (18.5 M).

Clearside Biomedical cash flow statement Correlations

0.14-0.14-0.07-0.080.03-0.18-0.16-0.060.050.15-0.080.4-0.04-0.150.08-0.11-0.10.22
0.14-0.070.3-0.55-0.05-0.53-0.630.360.33-0.11-0.270.06-0.38-0.2-0.440.44-0.350.08
-0.14-0.07-0.530.590.890.250.3-0.560.62-0.120.9-0.810.190.97-0.34-0.220.15-0.72
-0.070.3-0.53-0.25-0.620.02-0.040.95-0.02-0.07-0.520.03-0.03-0.540.010.59-0.01-0.09
-0.08-0.550.59-0.250.430.780.81-0.430.590.20.59-0.610.690.680.16-0.090.6-0.68
0.03-0.050.89-0.620.43-0.030.05-0.610.46-0.120.9-0.65-0.020.82-0.35-0.49-0.05-0.53
-0.18-0.530.250.020.78-0.030.96-0.190.320.240.24-0.430.860.410.020.390.83-0.6
-0.16-0.630.3-0.040.810.050.96-0.20.260.030.31-0.450.720.440.090.280.67-0.58
-0.060.36-0.560.95-0.43-0.61-0.19-0.2-0.15-0.32-0.560.12-0.31-0.620.00.52-0.290.07
0.050.330.62-0.020.590.460.320.26-0.150.140.42-0.630.380.62-0.210.250.3-0.67
0.15-0.11-0.12-0.070.2-0.120.240.03-0.320.14-0.040.140.67-0.010.17-0.090.690.0
-0.08-0.270.9-0.520.590.90.240.31-0.560.42-0.04-0.770.190.89-0.35-0.390.2-0.68
0.40.06-0.810.03-0.61-0.65-0.43-0.450.12-0.630.14-0.77-0.32-0.80.48-0.1-0.320.94
-0.04-0.380.19-0.030.69-0.020.860.72-0.310.380.670.19-0.320.360.00.280.98-0.52
-0.15-0.20.97-0.540.680.820.410.44-0.620.62-0.010.89-0.80.36-0.34-0.180.33-0.75
0.08-0.44-0.340.010.16-0.350.020.090.0-0.210.17-0.350.480.0-0.34-0.36-0.120.44
-0.110.44-0.220.59-0.09-0.490.390.280.520.25-0.09-0.39-0.10.28-0.18-0.360.31-0.25
-0.1-0.350.15-0.010.6-0.050.830.67-0.290.30.690.2-0.320.980.33-0.120.31-0.5
0.220.08-0.72-0.09-0.68-0.53-0.6-0.580.07-0.670.0-0.680.94-0.52-0.750.44-0.25-0.5
Click cells to compare fundamentals

Clearside Biomedical Account Relationship Matchups

Clearside Biomedical cash flow statement Accounts

201920202021202220232024 (projected)
Sale Purchase Of Stock3.4M258K499K129K116.1K110.3K
Change In Cash14.6M(5.3M)13.0M17.7M(19.5M)(18.5M)
Stock Based Compensation4.6M3.6M5.1M4.9M4.2M3.1M
Free Cash Flow(27.1M)(13.2M)(10.7M)(13.6M)(19.9M)(20.9M)
Begin Period Cash Flow8.4M23.0M17.6M30.7M48.4M50.8M
Other Cashflows From Financing Activities52K258K499K30.8M(1.3M)(1.2M)
Depreciation211K180K178K145K67K122.1K
Other Non Cash Items230K188K(998K)3.3M9.4M9.8M
Capital Expenditures88K25K55K246K1.8M1.9M
Total Cash From Operating Activities(27.1M)(13.1M)(10.7M)(13.4M)(18.1M)(19.0M)
Net Income(30.8M)(18.2M)376K(32.9M)(32.5M)(34.1M)
Total Cash From Financing Activities8.7M7.9M23.8M31.3M414K393.3K
End Period Cash Flow23.0M17.6M30.7M48.4M28.9M21.3M
Change In Working Capital(1.3M)1.1M(15.3M)11.2M720K756K
Investments33.0M(55K)0.0(246K)(1.8M)(1.9M)
Total Cashflows From Investing Activities(3.8M)32.9M(55K)(246K)(282.9K)(268.8K)
Change To Operating Activities(717K)1.8M(11.0M)10.3M11.9M12.5M
Change To Netincome4.8M3.7M4.1M4.9M5.7M3.6M
Change To Liabilities(5.6M)(631K)681K694K624.6K655.8K
Cash And Cash Equivalents Changes14.6M(5.3M)13.0M17.7M20.4M21.4M
Cash Flows Other Operating4.4M1.9M(16.0M)13.8M15.9M16.7M
Issuance Of Capital Stock13.6M12.0M23.3M566K1.7M1.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Clearside Biomedical is a strong investment it is important to analyze Clearside Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearside Biomedical's future performance. For an informed investment choice regarding Clearside Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.45)
Revenue Per Share
0.112
Quarterly Revenue Growth
(0.91)
Return On Assets
(0.44)
Return On Equity
(13.10)
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.